2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil

The STARTS-1 and -2 trials (Sildenafil in Treatment-Naive Children, Aged 1 to 17 Years, With Pulmonary Arterial Hypertension) and subsequent 2012 U.S. Food and Drug Administration (FDA) product labeling for sildenafil use in pediatric patients with pulmonary hypertension highlight many of the challe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Circ Cardiovasc Qual Outcomes
Asıl Yazarlar: Sable, Craig A., Ivy, D. Dunbar, Beekman, Robert H., Clayton-Jeter, Helene D., Jenkins, Kathy J., Mahle, William T., Morrow, William R., Murphy, Mary Dianne, Nelson, Robert M., Rosenthal, Geoffrey L., Stockbridge, Norman, Wessel, David L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5614492/
https://ncbi.nlm.nih.gov/pubmed/28663437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HCQ.0000000000000026
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller